MA41977A - Imidazopyrazinones utilisées comme inhibiteurs de pde1 - Google Patents

Imidazopyrazinones utilisées comme inhibiteurs de pde1

Info

Publication number
MA41977A
MA41977A MA041977A MA41977A MA41977A MA 41977 A MA41977 A MA 41977A MA 041977 A MA041977 A MA 041977A MA 41977 A MA41977 A MA 41977A MA 41977 A MA41977 A MA 41977A
Authority
MA
Morocco
Prior art keywords
imidazopyrazinones
pde1 inhibitors
pde1
inhibitors
imidazopyrazinones used
Prior art date
Application number
MA041977A
Other languages
English (en)
Other versions
MA41977B1 (fr
Inventor
Mikkel Jessing
Karsten Juhl
Jan Kehler
Morten Langgård
Lars Kyhn Rasmussen
Paulo Jorge Vieira Vital
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA41977A publication Critical patent/MA41977A/fr
Publication of MA41977B1 publication Critical patent/MA41977B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA41977A 2015-04-30 2016-04-29 Imidazopyrazinones utilisées comme inhibiteurs de pde1 MA41977B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201500261 2015-04-30
DKPA201500666 2015-10-29
DKPA201600202 2016-04-04
EP16720101.1A EP3288944B1 (fr) 2015-04-30 2016-04-29 Imidazopyrazinones utilisées comme inhibiteurs de pde1
PCT/EP2016/059583 WO2016174188A1 (fr) 2015-04-30 2016-04-29 Imidazopyrazinones utilisées comme inhibiteurs de pde1

Publications (2)

Publication Number Publication Date
MA41977A true MA41977A (fr) 2018-07-23
MA41977B1 MA41977B1 (fr) 2019-08-30

Family

ID=55910242

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41977A MA41977B1 (fr) 2015-04-30 2016-04-29 Imidazopyrazinones utilisées comme inhibiteurs de pde1

Country Status (42)

Country Link
US (4) US20160318939A1 (fr)
EP (1) EP3288944B1 (fr)
JP (1) JP6663930B2 (fr)
KR (1) KR102605759B1 (fr)
CN (1) CN107531714B (fr)
AU (1) AU2016256573B2 (fr)
BR (1) BR112017023182B1 (fr)
CA (1) CA2983563A1 (fr)
CL (1) CL2017002719A1 (fr)
CO (1) CO2017010399A2 (fr)
CY (1) CY1121806T1 (fr)
DK (1) DK3288944T3 (fr)
DO (1) DOP2017000254A (fr)
EA (1) EA031946B1 (fr)
EC (1) ECSP17072228A (fr)
ES (1) ES2735422T3 (fr)
GE (2) GEAP201914615A (fr)
GT (1) GT201700223A (fr)
HK (1) HK1252098B (fr)
HR (1) HRP20191180T1 (fr)
HU (1) HUE044244T2 (fr)
IL (1) IL255316B (fr)
JO (1) JO3627B1 (fr)
LT (1) LT3288944T (fr)
MA (1) MA41977B1 (fr)
ME (1) ME03414B (fr)
MX (1) MX375737B (fr)
MY (1) MY182382A (fr)
PE (1) PE20180121A1 (fr)
PH (1) PH12017501990B1 (fr)
PL (1) PL3288944T3 (fr)
PT (1) PT3288944T (fr)
RS (1) RS59051B1 (fr)
RU (1) RU2712219C2 (fr)
SG (1) SG11201708822PA (fr)
SI (1) SI3288944T1 (fr)
SM (1) SMT201900393T1 (fr)
TN (1) TN2017000428A1 (fr)
TW (1) TWI695838B (fr)
UA (1) UA123050C2 (fr)
WO (1) WO2016174188A1 (fr)
ZA (1) ZA201706847B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
WO2018073251A1 (fr) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones et pyrazolopyridinones en tant qu'inhibiteurs de pde1
AU2017350473A1 (en) * 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
WO2018078042A1 (fr) 2016-10-28 2018-05-03 H. Lundbeck A/S Traitements combinés comprenant l'administration d'imidazopyrazinones
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
DK3717488T3 (da) 2017-11-27 2021-12-13 Dart Neuroscience Llc Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
WO2019121840A1 (fr) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines et imidazo[1,5-b]pyridazines utilisées en tant qu'inhibiteurs de pde1
MX2020012628A (es) 2018-05-25 2021-01-29 Intra Cellular Therapies Inc Compuestos organicos.
WO2020210614A1 (fr) 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Composés organiques
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
WO2004099211A1 (fr) 2003-05-09 2004-11-18 Bayer Healthcare Ag Pyrazolopyrimidines substituees par 6-cyclylmethyle et 6-alkylmethyle
EP2168968B1 (fr) * 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC Inhibiteurs hétérobicycliques de la protéine kinase à anneau bicyclique substitué en 6,6
JP2008524331A (ja) * 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
US20080194592A1 (en) * 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008070095A1 (fr) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Nouvelles utilisations
RS52166B (sr) 2007-05-11 2012-08-31 Pfizer Inc. Amino-heterociklična jedinjenja
EP2227472A1 (fr) 2007-11-30 2010-09-15 Elbion Gmbh Imidazoý1,5-a¨pyrazines fusionnées à aryle et hétéroaryle comme inhibiteur de la phosphodiestérase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
KR20110063447A (ko) 2008-09-08 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도
BRPI0922809A2 (pt) * 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
EP2367430B1 (fr) * 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Composés organiques
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
WO2011153136A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
PL3042917T3 (pl) 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
EP2619208B1 (fr) * 2010-09-20 2016-11-09 Ironwood Pharmaceuticals, Inc. Composés imidazotriazinones
EP2619204A4 (fr) 2010-09-21 2014-08-27 Merck Sharp & Dohme Triazolopyrazinones comme antagonistes des récepteurs p2x7
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
BR112015007731B1 (pt) * 2011-10-10 2022-05-31 H. Lundbeck A/S Composto, composição farmacêutica que o compreende e uso do mesmo
BR112014018199A8 (pt) 2012-01-26 2021-03-02 H Lundbeck As inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
JP2013166727A (ja) * 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
CA2877146C (fr) 2012-06-18 2020-10-20 Dart Neuroscience (Cayman) Ltd Composes azolopyrimidine-5-(6h)-ones a thiophene et furane fusionnes substitues
KR102240326B1 (ko) 2013-03-15 2021-04-13 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
KR20160115936A (ko) 2014-02-19 2016-10-06 하. 룬드벡 아크티에셀스카브 알츠하이머병의 치료를 위한 bace1 저해제로서의 2-아미노-3,5,5-트리플루오로-3,4,5,6-테트라하이드로피리딘
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
WO2016042775A1 (fr) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Dérivé tricyclique
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
TW201639851A (zh) 2015-03-16 2016-11-16 大日本住友製藥股份有限公司 雙環咪唑衍生物
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
EP3334720A1 (fr) 2015-08-12 2018-06-20 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
WO2018073251A1 (fr) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones et pyrazolopyridinones en tant qu'inhibiteurs de pde1
WO2018078042A1 (fr) 2016-10-28 2018-05-03 H. Lundbeck A/S Traitements combinés comprenant l'administration d'imidazopyrazinones
AU2017350473A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders

Also Published As

Publication number Publication date
GT201700223A (es) 2018-12-19
MA41977B1 (fr) 2019-08-30
PT3288944T (pt) 2019-07-19
RU2017137514A (ru) 2019-05-31
DK3288944T3 (da) 2019-07-22
EA031946B1 (ru) 2019-03-29
PH12017501990A1 (en) 2018-03-26
TWI695838B (zh) 2020-06-11
HK1252098A1 (en) 2019-05-17
IL255316B (en) 2021-10-31
EA201792157A1 (ru) 2018-03-30
IL255316A0 (en) 2017-12-31
ECSP17072228A (es) 2018-02-28
CO2017010399A2 (es) 2018-01-05
GEAP201914615A (en) 2019-09-25
MX2017013785A (es) 2018-03-27
ME03414B (fr) 2020-01-20
MX375737B (es) 2025-03-06
PE20180121A1 (es) 2018-01-18
RS59051B1 (sr) 2019-08-30
CN107531714A (zh) 2018-01-02
LT3288944T (lt) 2019-07-25
HRP20191180T1 (hr) 2019-10-04
JO3627B1 (ar) 2020-08-27
EP3288944B1 (fr) 2019-06-12
US11472810B2 (en) 2022-10-18
AU2016256573B2 (en) 2019-11-21
CL2017002719A1 (es) 2018-04-20
ZA201706847B (en) 2019-01-30
UA123050C2 (uk) 2021-02-10
US20210238182A1 (en) 2021-08-05
HK1252098B (en) 2020-02-07
MY182382A (en) 2021-01-22
US10858362B2 (en) 2020-12-08
CY1121806T1 (el) 2020-07-31
SMT201900393T1 (it) 2019-09-09
WO2016174188A1 (fr) 2016-11-03
TN2017000428A1 (en) 2019-04-12
HUE044244T2 (hu) 2019-10-28
EP3288944A1 (fr) 2018-03-07
CN107531714B (zh) 2019-07-19
ES2735422T3 (es) 2019-12-18
AU2016256573A1 (en) 2017-12-14
RU2712219C2 (ru) 2020-01-27
CA2983563A1 (fr) 2016-11-03
PL3288944T3 (pl) 2019-11-29
KR20170140216A (ko) 2017-12-20
GEP20207058B (en) 2020-01-27
DOP2017000254A (es) 2018-01-15
KR102605759B1 (ko) 2023-11-23
TW201700477A (zh) 2017-01-01
PH12017501990B1 (en) 2021-01-13
US20160318939A1 (en) 2016-11-03
JP2018514552A (ja) 2018-06-07
SI3288944T1 (sl) 2019-08-30
JP6663930B2 (ja) 2020-03-13
US20170291903A1 (en) 2017-10-12
US10011606B2 (en) 2018-07-03
US20190062335A1 (en) 2019-02-28
BR112017023182B1 (pt) 2023-10-31
SG11201708822PA (en) 2017-11-29
BR112017023182A2 (fr) 2018-10-02
RU2017137514A3 (fr) 2019-07-17

Similar Documents

Publication Publication Date Title
CY2024003I1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
MA41977A (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
EP3541932A4 (fr) Inhibiteurs de crispr-cas9
LT3436461T (lt) Pirolotriazino junginiai kaip tam inhibitoriai
IL251420A0 (en) Triazolopyrazinones as pde1 inhibitors
EP3347008A4 (fr) Inhibiteurs de bêta-lactamases
DK3072835T3 (da) Fremgangsmåde til fremføring
EP3313828A4 (fr) Inhibiteurs de métallo-bêta-lactamases
MA41677A (fr) Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
MA44006A (fr) Inhibiteur pde1
EP3347333C0 (fr) Compositions inhibitrices de polymérisation
EP3334726A4 (fr) Compositions de plinabuline
DK3250182T3 (da) Dispergible sammensætninger
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
MA42597A (fr) 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
DK3717488T3 (da) Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
EP3394068A4 (fr) Inhibiteurs de tdo2
EP2976340A4 (fr) Cycloalkylnitrile pyrazolopyridones utilisées comme inhibiteurs de la janus kinase
IL248078B (en) Halogenated quinazolin-thf-amines as pde1 inhibitors
DK3331498T3 (da) Nasalsammensætning
DK3316857T3 (da) Multifasiske sammensætninger
IL246718A0 (en) Hexahydrofuropyrroles as pde1 inhibitors
EP3414334C0 (fr) Procédé
EP3286306A4 (fr) Nouveau procédé
EP3368013C0 (fr) Formulations liquides de buprénorphine